Results 11 to 20 of about 26,004 (264)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety

BMC Cancer, 2022
Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with a poor prognosis. Approximately 20% of TNBC has been found to express programmed death ligand 1 (PD-L1), making it a potential therapeutic target.
K. Sharmni Vishnu, Thin Thin Win, Saint Nway Aye, Arun Kumar Basavaraj   +3 more
doaj   +1 more source

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2023
Background: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC.
Rui Wan, Yanrong Guo, Xuezhi Hao, Zhijie Wang, Jianchun Duan, Jie Wang   +5 more
doaj   +1 more source

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

Biomedicines, 2023
Taxanes (paclitaxel and docetaxel) are one of the most useful classes of anticancer drugs. Taxanes are highly hydrophobic; therefore, these drugs must be dissolved in organic solvents (polysorbate or Cremophor EL), which contribute to their toxicities ...
Md Sazzad Hassan, Niranjan Awasthi, Saisantosh Ponna, Urs von Holzen   +3 more
doaj   +1 more source

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel

Case Reports in Oncology, 2023
We present a rare phenomenon of a soft tumor hanging on the woman’s left upper arm that underwent necrosis from the distal aspect during chemotherapy for pancreatic cancer. The benign tumor, pedunculated lipofibroma, originally had normal color for 10 years and then became necrotic when she was treated with gemcitabine and nab-paclitaxel.
Hiraku Kokubu, Takeshi Nakanishi, Takeshi Kato, Noriki Fujimoto   +3 more
openaire   +3 more sources

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer

BMC Cancer, 2021
Background Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be ...
Haili Lu, Siluo Zha, Wei Zhang, Qiang Wang, Daozhen Jiang, Xinyun Xu, Xiangmin Zheng, Ming Qiu, Chengxiang Shan   +8 more
doaj   +1 more source

Macular Cystoid Edema Induced by Nab-Paclitaxel

Acta Médica Portuguesa, 2022
A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively.
Sara Alves Pereira, Carolina Vale, Jorge Moreira, Filipa Sampaio   +3 more
openaire   +4 more sources

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. [PDF]

, 2018
BackgroundWe performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours.MethodsPatients were given fixed dose gemcitabine plus ...
Agarwal, Rishi, Bass, Allison, Bean, Stacie, Byers, Lauren, Falchook, Gerald, Fu, Siqing, Hess, Kenneth, Hong, David, Janku, Filip, Karp, Daniel, Kato, Shumei, Kurzrock, Razelle, Lim, JoAnn, Meric-Bernstam, Funda, Naing, Aung, Nguyen, Ly, Pant, Shubham, Piha-Paul, Sarina, Sen, Shiraj, Subbiah, Vivek, Tang, Chad, Tsimberidou, Apostolia, Westin, Shannon, Wu, Xifeng, Ye, Yuanqing   +24 more
core   +2 more sources

A bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer [PDF]

, 2014
© 2014 Chan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited ...
AJ Sutton, C Louvet, D Cunningham, D Li, DC Hoglin, DD Von Hoff, DG Altman, Doug Coyle, E Poplin, F Di Costanzo, G Colucci, G Colucci, H Ueno, HA Burris 3rd, Henry Lam, JD Berlin, Jonathan R. Brody, JP Higgins, Kelly Lien, Kelvin Chan, Keya Shah, M Ozaka, MH Kulke, MJ Moore, MK Parmar, PA Philip, PF Peddi, R Herrmann, R Warsame, S Boeck, T Conroy, T Li, V Heinemann, W Scheithauer, X Wang, Y Nakai, Yoo-Joung Ko   +36 more
core   +7 more sources

Comparison of Peripheral Neuropathy Induced by Standard and Nanoparticle Albumin–Bound Paclitaxel in Rats

Journal of Pharmacological Sciences, 2011
.: Nanoparticle albumin–bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel.
Yuji Yamashita, Nobuaki Egashira, Ken Masuguchi, Soichiro Ushio, Takehiro Kawashiri, Ryozo Oishi   +5 more
doaj   +1 more source

Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models [PDF]

, 2016
Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis.
Awasthi, Niranjan, Grojean, Meghan, Monahan, Sheena, Schwarz, Margaret A., Schwarz, Roderich E., Scire, Emily, Zhang, Eric   +6 more
core   +1 more source